Literature DB >> 26137414

Characterization of myeloid leukocytes and soluble mediators in pancreatic cancer: importance of myeloid-derived suppressor cells.

Svetlana Karakhanova1, Julia Link1, Moritz Heinrich1, Ivan Shevchenko2, Yuhui Yang3, Matthias Hassenpflug1, Henriette Bunge1, Katharina von Ahn1, Ramona Brecht1, Andreas Mathes1, Caroline Maier1, Viktor Umansky4, Jens Werner5, Alexandr V Bazhin5.   

Abstract

Pancreatic ductal adenocarcinoma (PDAC) represents one of the deadliest cancers in the world. PDAC cells activate tumor-specific immune responses but simultaneously trigger a strong immunosuppression. We showed that PDAC cells produce high amount of chronic inflammatory mediators and PDAC tumors build an immunosuppressive cytokine milieu, which correlates with tumor progression. We observed a low frequency of dendritic cells (DC) and a pronounced accumulation of macrophages and myeloid-derived suppressor cells (MDSC) in murine PDAC tumors. A strong accumulation of MDSC has also been demonstrated in the peripheral blood of resected PDAC patients. While DC and macrophages seem not to play a significant role in this PDAC model in the context of immunosuppression, MDSC are highly suppressive, and their accumulation is associated with an increase in intratumoral VEGF concentration during the PDAC progression. Application of the phosphodiesterase-5 inhibitor sildenafil led to a prolonged survival of PDAC-bearing female mice, which was due to the decrease in MDSC frequencies and in the systemic VEGF level. This led to a restoration of anticancer immune responses, manifested in the recovery of T lymphocyte functions and in an increase in the frequency of conventional CD4+ T cells in tumors and IFNγ level in serum of PDAC-bearing mice. Thus, MDSC are strongly involved in the PDAC-associated immunosuppression and that their depletion could create new approaches for therapy of PDAC.

Entities:  

Keywords:  ARG-1, arginase-1; DC, dendritic cells; MDSC; MDSC, myeloid-derived suppressor cells; NO, nitric oxide; PDAC, pancreatic ductal adenocarcinoma; TIL, tumor-infiltrating leukocytes; Tregs, regulatory T cells; immune suppression; orthotopic Panc02 model; pancreatic adenocarcinoma

Year:  2015        PMID: 26137414      PMCID: PMC4485765          DOI: 10.1080/2162402X.2014.998519

Source DB:  PubMed          Journal:  Oncoimmunology        ISSN: 2162-4011            Impact factor:   8.110


  41 in total

Review 1.  Early detection of pancreatic carcinoma.

Authors:  Christophe Rosty; Michael Goggins
Journal:  Hematol Oncol Clin North Am       Date:  2002-02       Impact factor: 3.722

2.  In vivo immunoregulatory properties of the novel mitochondria-targeted antioxidant SkQ1.

Authors:  Yuhui Yang; Svetlana Karakhanova; Sabine Soltek; Jens Werner; Pavel P Philippov; Alexandr V Bazhin
Journal:  Mol Immunol       Date:  2012-05-14       Impact factor: 4.407

3.  Sex-dependent effect of melatonin on systemic erythematosus lupus developed in Mrl/Mpj-Faslpr mice: it ameliorates the disease course in females, whereas it exacerbates it in males.

Authors:  Antonio J Jimenez-Caliani; Silvia Jimenez-Jorge; Patrocinio Molinero; Jose M Fernandez-Santos; Ines Martin-Lacave; Amalia Rubio; Juan M Guerrero; Carmen Osuna
Journal:  Endocrinology       Date:  2005-12-22       Impact factor: 4.736

Review 4.  Pancreatic carcinoma.

Authors:  A L Warshaw; C Fernández-del Castillo
Journal:  N Engl J Med       Date:  1992-02-13       Impact factor: 91.245

5.  Elevated myeloid-derived suppressor cells in pancreatic, esophageal and gastric cancer are an independent prognostic factor and are associated with significant elevation of the Th2 cytokine interleukin-13.

Authors:  Rachel F Gabitass; Nicola E Annels; Deborah D Stocken; Hardev A Pandha; Gary W Middleton
Journal:  Cancer Immunol Immunother       Date:  2011-06-05       Impact factor: 6.968

6.  Cooperative induction of a tolerogenic dendritic cell phenotype by cytokines secreted by pancreatic carcinoma cells.

Authors:  Graziella Bellone; Anna Carbone; Carlo Smirne; Tiziana Scirelli; Alessandra Buffolino; Anna Novarino; Alessandra Stacchini; Oscar Bertetto; Giorgio Palestro; Claudio Sorio; Aldo Scarpa; Giorgio Emanuelli; Ulrich Rodeck
Journal:  J Immunol       Date:  2006-09-01       Impact factor: 5.422

7.  Induction and chemotherapeutic response of two transplantable ductal adenocarcinomas of the pancreas in C57BL/6 mice.

Authors:  T H Corbett; B J Roberts; W R Leopold; J C Peckham; L J Wilkoff; D P Griswold; F M Schabel
Journal:  Cancer Res       Date:  1984-02       Impact factor: 12.701

8.  Rosiglitazone and Gemcitabine in combination reduces immune suppression and modulates T cell populations in pancreatic cancer.

Authors:  Stephanie K Bunt; Ashley M Mohr; Jennifer M Bailey; Paul M Grandgenett; Michael A Hollingsworth
Journal:  Cancer Immunol Immunother       Date:  2012-08-05       Impact factor: 6.968

9.  Dynamics of the immune reaction to pancreatic cancer from inception to invasion.

Authors:  Carolyn E Clark; Sunil R Hingorani; Rosemarie Mick; Chelsea Combs; David A Tuveson; Robert H Vonderheide
Journal:  Cancer Res       Date:  2007-10-01       Impact factor: 12.701

10.  Overcoming immunosuppression as a new immunotherapeutic approach against pancreatic cancer.

Authors:  Alexandr V Bazhin; Jagadeesh Bayry; Viktor Umansky; Jens Werner; Svetlana Karakhanova
Journal:  Oncoimmunology       Date:  2013-07-23       Impact factor: 8.110

View more
  37 in total

1.  Macrophage PI3Kγ Drives Pancreatic Ductal Adenocarcinoma Progression.

Authors:  Megan M Kaneda; Paola Cappello; Abraham V Nguyen; Natacha Ralainirina; Chanae R Hardamon; Philippe Foubert; Michael C Schmid; Ping Sun; Evangeline Mose; Michael Bouvet; Andrew M Lowy; Mark A Valasek; Roman Sasik; Francesco Novelli; Emilio Hirsch; Judith A Varner
Journal:  Cancer Discov       Date:  2016-05-13       Impact factor: 39.397

2.  PAP/REG3A favors perineural invasion in pancreatic adenocarcinoma and serves as a prognostic marker.

Authors:  Jérémy Nigri; Meritxell Gironella; Christian Bressy; Elena Vila-Navarro; Julie Roques; Sophie Lac; Caroline Bontemps; Coraline Kozaczyk; Jérôme Cros; Daniel Pietrasz; Raphaël Maréchal; Jean-Luc Van Laethem; Juan Iovanna; Jean-Baptiste Bachet; Emma Folch-Puy; Richard Tomasini
Journal:  Cell Mol Life Sci       Date:  2017-06-27       Impact factor: 9.261

Review 3.  Myeloid-derived suppressor cells and their role in pancreatic cancer.

Authors:  M Pergamo; G Miller
Journal:  Cancer Gene Ther       Date:  2016-12-02       Impact factor: 5.987

Review 4.  Direct and indirect regulation of the tumor immune microenvironment by VEGF.

Authors:  Yuqing Zhang; Rolf A Brekken
Journal:  J Leukoc Biol       Date:  2022-04-25       Impact factor: 6.011

5.  Frequent adaptive immune responses against arginase-1.

Authors:  Evelina Martinenaite; Rasmus Erik Johansson Mortensen; Morten Hansen; Morten Orebo Holmström; Shamaila Munir Ahmad; Nicolai Grønne Dahlager Jørgensen; Özcan Met; Marco Donia; Inge Marie Svane; Mads Hald Andersen
Journal:  Oncoimmunology       Date:  2017-12-26       Impact factor: 8.110

Review 6.  Myeloid-derived suppressor cells in B cell malignancies.

Authors:  Yaghoub Yazdani; Mousa Mohammadnia-Afrouzi; Mehdi Yousefi; Enayat Anvari; Ghasem Ghalamfarsa; Hadi Hasannia; Sanam Sadreddini; Farhad Jadidi-Niaragh
Journal:  Tumour Biol       Date:  2015-09-02

Review 7.  Myeloid derived suppressor cells and the release of micro-metastases from dormancy.

Authors:  Saraswoti Khadge; Kathryn Cole; James E Talmadge
Journal:  Clin Exp Metastasis       Date:  2021-05-20       Impact factor: 4.510

Review 8.  Trials and tribulations of pancreatic cancer immunotherapy.

Authors:  Daniel R Principe; Murray Korc; Suneel D Kamath; Hidayatullah G Munshi; Ajay Rana
Journal:  Cancer Lett       Date:  2021-02-04       Impact factor: 9.756

Review 9.  Vascular Endothelial Growth Factor, a Key Modulator of the Anti-Tumor Immune Response.

Authors:  Mannon Geindreau; François Ghiringhelli; Mélanie Bruchard
Journal:  Int J Mol Sci       Date:  2021-05-04       Impact factor: 5.923

Review 10.  Antiangiogenic therapy reverses the immunosuppressive breast cancer microenvironment.

Authors:  Wuzhen Chen; Lesang Shen; Jingxin Jiang; Leyi Zhang; Zhigang Zhang; Jun Pan; Chao Ni; Zhigang Chen
Journal:  Biomark Res       Date:  2021-07-22
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.